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Abstract: Background and Objectives: There is confusion as to which component of the Opuntia spp.
cacti has demonstrated anti-hyperglycemic effects or anti-diabetic properties. It is important to clarify
these health benefits due to the increasing need for prevention and treatment of chronic diseases.
The aim of this review is to identify the effects of Opuntia spp. cacti consumption on biomedical
measures; glucose and insulin with consideration of its’ components; fruit, leaf and combined or
unidentified Opuntia spp. products. Materials and Methods: Prior to commencing the searches, this
systematic review was registered with PROSPERO (CRD42018108765). Following the PRISMA 2009
guidelines, six electronic databases (Food Science and Technology Abstracts (EBSCO), Medline,
Scopus, CINAHL, Web of Science and Cochrane) were searched for articles investigating the effect
of Opuntia spp. consumption on glucose and insulin in humans. Results: Initially, 335 articles were
sourced and filtered by exclusion criteria (human interventions, control trials and articles published
in English) resulting in 20 relevant articles. The included studies were characterized by such plant
components as fruit (n = 4), cladode (n = 12), and other Opuntia spp. products (n = 4), further separated
by clinical populations (‘healthy’, hyperlipidemic, hypercholesterolemic, Type 2 Diabetes Mellitus).
The findings of this review indicate variations in effects between cacti components and products.
Cladode and select Opuntia spp. products predominately demonstrated significant reductions in
serum glucose and insulin, indicating potential as a functional food candidate. Prickly Pear fruit was
predominately reported to have no significant effects on glucose or insulin. The quality of evidence
appeared to vary based on the type of Opuntia spp. product used. Studies that used specifically the
fruit or cladode had high risk of bias, whereas studies which used combined Opuntia spp. products
had a lower risk of bias. Numerous mechanisms of action were proposed where positive findings
were reported, with emphasis on dualistic glucose-dependent and independent actions, however,
mechanisms require further elucidation. Conclusion: Currently, there is a lack of evidence to support
the recommendation of using Opuntia spp. fruit products as an alternative or complementary therapy
in the reduction of risk or management of Type 2 Diabetes Mellitus. The Cladode does however show
promise in potential glucose-lowering effects which warrant further investigation.
Keywords: Opuntia; prickly pear; cactus pear; cladode; glucose; insulin; human; systematic review
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1. Introduction
The prevalence of Type 2 Diabetes Mellitus (T2DM) and the corresponding demand for its management
is proving to be a global economic burden [1]. Various strategies, including dietary management,
exercise-based therapies, novel drug development, personalized medicine, pharmacotherapy,
pathogenesis, traditional medicines, and combined anti-diabetic or ‘anti-hyperglycemic’ therapies are
prioritized as various methods for treatment and prevention of T2DM globally [1].
Herbal treatments and traditional plant-based medicines have become increasingly popular,
as convenient and low-cost options with potentially fewer side effects [1]. Herbal or plant-based
anti-hyperglycemic treatments are reportedly targeted to biochemical pathways, including
antioxidant/free radical pathways based on hyperglycemia being associated with mitochondria
overproduction of free radicals [1,2]. Additionally, there is increasing interest in management
strategies for T2DM and its prevention based on alternative low-cost nutrition strategies, including
plant-based functional-foods [2]. However, currently, consensus has only been reached regarding the
anti-hyperglycemic effect relating to the high-fiber content of many of the proposed anti-hyperglycemic
functional foods. This is primarily based on the fiber content slowing the rate of digestion and the
resultant altered rate of glucose absorption [2].
Worldwide, there is a focus on sustainable and responsible preventative health interventions,
with the emphasis on socio-political, economic and environmental factors [3]. The social push to
include environmental factors has led to the consideration of the effectiveness of low-resource intensive
plant-based treatments for the maintenance and prevention of T2DM. This includes the potential
therapeutics derived from cacti [3,4]. Specifically, Opuntia spp. cacti, with a strong history of use
as a treatment of hyperglycemia in traditional medicine [4], will be the focus of this systematic
review. The Opuntia spp. cacti is utilized as a source of food, hedge plant, or as an ornamental plant,
particularly in arid and drought-affected regions, becoming more relevant with environmental cases
of desertification [5–8]. The cacti as a crop is utilized, particularly on non-productive agricultural
lands, for its resources, that include the fruit, the Prickly Pear (PP) and leaf, the cladode [5–8].
The Opuntia spp. cacti is reported to have ‘anti-hyperglycemic’ and ‘anti-diabetic’ properties in
humans and it is prescribed in many traditional and complementary therapies around the world [9–12].
However, confusion exists within the literature as to which principal cacti component is potentially
responsible for such effects. Clarification of this issue could enhance the use of PP for treatment,
maintenance, and prevention of chronic diseases and affect progress in the development of new
potential anti-hyperglycemic agents.
To be able to further consider Opuntia spp. components for new anti-hyperglycemic agents, there
is a need to identify which component(s), if any, are the true source of any potential anti-hyperglycemic
effects of Opuntia spp. There are obvious compositional variations between the leaf and fruit which
require investigation to define any possible resultant health associations [4]. The fruit of the cacti
is also referred to as the ‘cactus fruit’ or ‘Indian fig’ and also as the PP [6,7] is predominantly
known for relatively high levels of macro- and micronutrients including fiber, mineral composition,
numerous amino acids; and significant lipid and phytosterol content [13–17]. In addition, there are a
number of different bioactive compounds found in PP such as polyphenols [18,19], flavonols [19–21]
and betalains [18,22,23], as well as considerably strong antioxidant characteristics [17,18,20,21,24–31].
The PP fruit is commonly consumed fresh, although it can be formulated into several different including
dried fruits, tea’s, jams, drinks, tinctures and dietary supplements [6,32,33].
The Opuntia spp. cacti leaves, often termed the ‘cladode’ are commonly eaten as a broiled or grilled
food product. The cladodes’ compositional content varies substantially from the fruit, although it does
share common features to include high fiber, mineral, and selection of different bioactives [34]. Similar
to PP, the cladode has been extensively investigated for bioactive compounds to include extensive
phenolic analysis and antioxidant characterization of various extracts [34]. More recently, the cladode
was used in various forms in the food and supplements market such as various pickled products, fiber
powders, or capsule-based supplements [35,36].
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Therefore, based on the current findings, the primary aim of this systematic literature review is to
examine the evidence drawn from well-controlled human clinical trials on the effect of consumption
on Opuntia spp. cacti on blood glucose (GLU) and insulin levels (INS) in humans. The outcomes of
this systematic review will potentially assist clinicians with decisions regarding the use of Opuntia spp.
product (fruit, leaf or combined) consumption, for improvement of T2DM associated clinical measures
such as hyperglycemia or insulin regulation.
2. Materials and Methods
This systematic literature review was conducted following the PRISMA 2009 guidelines [37],
and searches were performed in six electronic databases: Food Science and Technology Abstracts
(EBSCO), Medline, Scopus, CINAHL, Web of Science and Cochrane databases. The generated results
were screened for relevance by title, abstracts and full text (Figure 1), with additional hand searches
of included articles reference lists. Results were limited to human quantitative intervention trials
based on the consumption of Opuntia spp., investigating the effects on blood GLU or INS resistance
parameters, published in English, in peer-reviewed journals since the journal inception. No limitations
were made regarding age, gender, race or ethnicity. This systematic literature review is also registered
with the PROSPERO registry of the systematic literature reviews held at the University of York
(CRD42018108765).
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2.1. Search Terminology and Selection Criteria
The following search terms were used, to produce the database outputs: “(‘Opuntia’ OR “Prickly
Pear” OR “Cactus fruit” OR “Tuna fruit” OR “Indian fig” OR ‘Nopal’ OR ‘Cladode’ OR “Cactus
Leaf” OR ‘Stems’) AND (‘Glucose’ OR ‘Blood glucose’ OR ‘Glucose tolerance’ OR ‘Impaired glucose’
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OR ‘Oral glucose’ OR ‘Glucose metabolism’ OR ‘glycemia’ OR ‘Glycaemia’ OR ‘Hyperglycemia’ OR
‘Fasting blood glucose’ OR ‘Glycemic Index’ OR ‘HOMA’ OR ‘QUICKI’ OR ‘GI’ OR ‘Insulin’ OR
‘Insulin resistance’ OR ‘Plasma insulin’ OR ‘Insulin secretion’). Eligibility for inclusion was determined
via satisfaction of criteria; human, in vivo, quantitative intervention trials with control groups or
placebo, consumption of Opuntia spp. and published since journal inception until September 2018 (5th).
The reference lists of included articles were searched for similar phrases and screened for relevance.
2.2. Data Extraction and Outcomes of Interest
Data extraction was conducted independently by two reviewers (C.G., and N.N.) who assessed
the eligibility of imported EndNote (v8, Thomas Reuters, Eagan, MN, USA) citations from the database
outputs, after removing duplicates. Excluded articles within the screening of titles, abstracts, and
full-text articles were excluded on consensus, where disagreement was resolved via discussion. In total,
37 full-text articles were selected for review; and only 20 were included in this systematic review.
Prompting reference list searches of included articles, no further articles were identified as suitable for
inclusion in this review. Primary outcomes of interest for this systematic review included measures of
blood or serum GLU and INS, including biochemical assays, or well-known tools, Homeostatic Model
Assessment (HOMA) and ‘Quantitative Insulin Sensitivity Check Index’ (QUICKI).
2.3. Data Analysis
Overall studies were evaluated on; risk of bias; study characteristics to include sample size; and
participant characteristics including age and gender, study design and intervention. More specifically
tools of analysis and reported outcomes were also analyzed to make meaningful conclusions. Due to
the heterogenicity of different food products and non-quantifiable composition of some macro-
and micronutrients in the provided treatments (food and/or supplement) a meta-analysis was not
deemed suitable.
2.4. Risk of Bias
The risk of bias for each included study was evaluated using the ‘Cochrane Risk of Bias Tool’ [38].
The forms of bias considered included; selection, performance, detection, attribution, reporting and
‘other’ biases, which were scored either ‘low’, ‘high’ or ‘unclear’.
3. Results
3.1. Search in Literature
Of the 335 results, 20 articles met the inclusion criteria (Figure 1). After removal of duplicates, the
included articles were substantially reduced by title and abstract relevance screening (258 removed).
Searches of the included article reference lists which did not yield any additional studies were
unsuccessful in recruiting additional literature for inclusion. Remaining articles were progressed to
full-text screening, where results were filtered to include 20 manuscripts investigating consumption
associated effects of various components of the Opuntia spp. on blood GLU and INS resistance
measures. Of the included studies; four studies [39–42] investigated the Opuntia spp. fruit (Table 1),
twelve studies [43–55] investigated the Opuntia spp. cladode (Table 2), and four studies [36,51,56,57]
investigated unspecified or combinations of both the Opuntia spp. fruit and cladode (Table 3).
The included studies were scored for risk of bias (Table 4) by two researchers (C.G. and N.N.)
following the Cochrane Risk of Bias Tool [38]. Investigations into single plant products (fruit; cladode)
tended to have a high selection (3; 3) and performance bias (3; 9), with the exception of Wiese et al.
(2004) [41] and Bacardi-Gascon et al. (2007) [55]. Across all included studies, detection bias was rated as
high, or unclear, if not detailed within the methodology of the article. Reporting bias was consistently
low for all included studies.
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Table 1. The Summary of the effect of Opuntia spp. fruit consumption on blood glucose levels and insulin in human trials [39–42].
Author (Year) Participant, Sample Size Aim Intervention Relevant Outcome Results (C vs. T))
Khouloud et al.
(2016) [39]
Healthy M (n = 22)
T (n = 11)
Age: 20.91 ± 1.22 years
C (n = 11)
Age: 21.00 ± 0.84 years
Effect of flavonoid standardized PP fruit
(Opuntia ficus indica; purple; peeled) juice
consumption on cardiovascular,
oxidative stress and biochemical
parameters during exercise
Duration: 2 w
T: 3 × day 30 mL/day PP juice;
C: No antioxidants: 150 mL/day
RCT
Fasted
GLU
Before vs. After Exercise:
↑ GLU (p = 0.01) for both
Treatment and Control groups
No difference between groups
were reported
Wolfram et al.
(2002) [40]
M (n = 24)
Age: 37–55 y (45 ± 4.7 years)
Group 1: (n = 12)
‘Hypercholesterolemic’
Group 2: (n = 12)
‘Hyperlipidemic’
The effect of PP (Opuntia Robusta) pulp
pectin on GLU and lipid metabolism
Duration: 16 w
Pre-running phase:
Diet: 7506 kJ (625 kJ 50% fibers and 50%
CHO; 8 w)
Phase 2: Replaced diet fiber and CHO with
fresh 250g/day of PP pulp (8 weeks)
Parallel CT
Fasted (14 hrs.):
GLU
INS
↓ GLU between phase 1 and 2
(p < 0.005) for both groups 1 and 2
↓ INS between phase 1 and 2 for
group 1 (p < 0.005)
INS group 2 = NS (p > 0.05)
Pimienta et al.
(2008) [42]
Phase 1:
‘Healthy’ M (n = 14)
Age: 22.4 ± 3.2 years
Phase 2:
‘T2DM participants’
F (n = 10)
Age: 42.4 ± 3.3 years
The effects of yellow PP fruit peel on
health males (single consumption) and
diabetic females(Chronic; 5 weeks)
Phase 1:
Single consumption
Treatment: 250 g fruit peel and GLU solution
Control: 75 g GLU (solution)
Control trial
Phase 2:
Duration: 5 w
Fasted; 3 × 50 g PP peel/week
Control: Baseline measurements
Control Trial
OGTT (12 h fasted)
Time −20, 0, 20, 30, 60, 80,
100, 120, 140, 160, 190, 200
min
Phase 1 and 2:
GLU
INS
Phase 1:
↓ GLU: treatment vs. control
(40 min) (p < 0.05), all other time
points NS (p > 0.05)
↑ INS treatment NS (p > 0.05)
Phase 2:
INS ‘healthy’ and diabetics NS
(p > 0.05)
GLU: diabetics NS (p > 0.05)
Wiese et al.
(2004) [41]
‘Healthy M&F with history of at
least one hangover
(n = 55)
M (n = 37)
F (n = 18)
Age: 21–25 years
The effect of Opuntia ficus indica PP fruit
extract in reducing symptoms of severity
from alcohol hangover
Length: Single consumption
Induced hangover: Consumption of 1.75 g of
alcohol/kg (Low: vodka, gin, rum; high:
bourbon, scotch, tequila) with standard meal
(cheeseburger, French fries and soda)
Treatment: 2× capsule of Opuntia ficus indica
PP fruit extract
Placebo: 2× capsule
2 w washout
Randomized Control Cross-Over Trial
GLU
Baseline VS. placebo: NS
(p > 0.05)
Placebo VS. treatment: NS
(p > 0.05)
BMI: Body Mass Index; PP: Prickly Pear; YYIRT: Yo-Yo Intermitted Recovery Test; GLU: Blood Glucose; NS: Not Significant; NR: Not Reported; CHO: Carbohydrate; h-hours; INS: Serum
insulin; ↓: Decrease; ↑: Increase.
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Table 2. The summary of the effect of Opuntia spp. cladode consumption on blood glucose and insulin in human trials [43–55].
Author (Year) Participant, Sample Size Aim Intervention Relevant Outcomes Results (Treatment vs. Placebo)
Acute Results
Frati et al.
(1983) [45]
‘Healthy’ Males (n = 5)
Age: 28–35 years
The effect of ‘Nopal’ (CLD;
Opuntia streptacantha)
consumption on OGTT,
on GLU and INS in
healthy males
Length: Single consumption
Treatment:
(1) 75 g GLU
(2) 75 g GLU + 100 g broiled CLD stems (20 min before OGTT)
Control trial
GLU (mg/dl)
INS (µU/mL)
Time: 0, 60, 120, 180 min
GLU: ↓ after meal CLD consumption
0 min (p < 0.01), 60 min (p < 0.05),
120 min (p < 0.05), 180 min (p < 0.01)
INS: ↓ after meal CLD consumption;
0 min (p < 0.01), 60 min (p < 0.01),
120 min (p < 0.01), 180 min (p < 0.02)
T2DM
Frati et al.
(1987) [48]
‘Healthy’ Adults
(n = 16)
Group 1: (n = 5)
Group 2: (n = 6)
Group 3: (n = 5)
The effect of CLD
(Opuntia sp.) consumption
on blood GLU and INS
response, to dextrose in
OGTT
Length: Single Consumption
Group 1: 12 h fasted + treatment
Group 2: OGTT (25 g GLU), CLD given after time 0, before GLU load
Group 3: OGTT (25 g GLU) + treatment
CLD Treatment: 100 g on CLD, ground and mixed with 100 g of water
Controls in each group:
12 h fasting:
OGTT + Nopal load
OGTT + 200 mL water
GLU
INS
Blood collection:
Group 1 and 3: 0, 30, 60,
120, 180 min
Group 2: 0, 5, 15, 30, 60,
120 min
CLD consumption on GLU and
INS = NS (p > 0.05)
GLU: NS (p > 0.05); except for: Group 1
vs Group 2 (CLD vs. OGTT+CLD):
60 min; 180 min (p < 0.025)
Frati et al.
(1990) [54]
T2DM
(n = 8; 2 Males; 6 Females)
Age: 45–68 years
(Mean: 55 years)
The effect of Opuntia ficus
indica on hyperglycemia
(CLD) in T2DM
Length: single consumption
Treatments: (500 g)
(1) Entire Broiled CLD
(2) Blended and broiled CLD
(3) Blended CLD
(4) Blended and heated (60 ◦C) CLD
Cross-over trial
Fasted (12 h) blood: 40, 60,
120, 180 min
GLU
↓ GLU at 120 min and 190 min (VS.
control (baseline); p < 0.01)
NS differences between heated and
unheated (p > 0.05)
Frati et al.
(1991) [44]
Group 1:
(n = 8; 2 Males; 5 Females)
T2DM
Age:36–65 years
(50 years)
Group 2:
(n = 6; 3 Females; 3 Male)
‘Healthy’ volunteers
Age: 15–45 years
(25 years)
The effect of two
sequential doses of
Opuntia streptacantha
stems blood GLU and INS
Length: single consumption
Treatment:
500 g broiled cladode
Test A:
Ingestion at time 0 h, 2 h; 300 mL water at 4 h
Test B:
Ingestion at time 0 h,
300 mL water at 2 h, 4 h
Test C (control):
300mL water at 2 h, 4 h
Control-trial
Blood: 0,2,4 and 6 h
GLU
Test A vs Test B:
↓GLU: Group 1 first ingestion at 2, 4 and
6 h (p < 0.001)
NS: ‘Healthy’ participants (p > 0.05)
Frati et al.
(1991) [43]
Group 1: T2DM
(n =14; 9 Males, 5 Females)
Age: 32–56 years
(Mean: 43.4 years);
Group 2: ‘Healthy’ (n = 14;
9 Males; 5 Females)
Age: 23–51 years
(Mean: 32.7 years)
The effect of ‘Nopal’ (CLD;
Opuntia streptacantha)
consumption on blood
and GLU of T2DM
Length: Single consumption
Group 1 and 2 treatments: (fasted) 500g grilled CLD
(Opuntia streptacantha); or 400 mL Water
Randomized control trial
GLU
INS
GLU:
↓ in T2DM (Vs Control) (p < 0.005,
60 min; p < 0.005 120; p<0.001 180 min)
‘Healthy’- NS (p > 0.05)
INS: (n = 7, each Group)
↓- T2DM (vs. control) (p < 0.001; 120 min,
180 min)
‘Healthy’: NS
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Table 2. Cont.
Author (Year) Participant, Sample Size Aim Intervention Relevant Outcomes Results (Treatment vs. Placebo)
Acute Results
Frati et al.
(1988) [47]
T2DM (n = 16)
Group 1: (n = 16; 9 Males, 7
Females)
Age: 32–67 years,
Mean: 48.3±11.4 years (n = 12
received sulfonylureas)
Group 2: (n = 10; 6 Males; 4
Females)
Age: 31–67 years
Mean: 46.2 ± 10.8 y; (n = 10
received sulfonylureas)
Group 3: (n = 6; 4 Males; 2
Females)
Age: 33–66 years
Mean: 48 ± 11.7 years (n = 4
received sulfonylureas)
The effect of CLD
(Opuntia streptacantha)
consumption on T2DM
Length: Single consumption
Hyperglycemic agents discontinued 72 h before trial.
Treatment:
Group 1: 500 g of Broiled CLD
Group 2: 300 mL water
Group 3: 500 g of Broiled Squash (zucchini)
Randomized control-trial
GLU
INS
(fasted; 12 h)
Time: 0, 60, 120, 180 min.
GLU: ↓ (vs. basal; p < 0.001)
Group 1 vs. 2: ↓ 60 min (p< 0.025);
120 min (p < 0.001); 180 min (p < 0.001)
Group 2: No change
Group 3: NS (p > 0.05)
INS: ↓ Serum INS
Group 1 vs. 2: ↓ 120 min, 180 min
(p < 0.001)
Group 3: NS (p > 0.05)
Lopez-Romero
et al. (2014)
[50]
Study 1:
‘Healthy’ (n = 7; 3 Males, 4
Females)
Age: 26.3 ± 1.2 years;
BMI: 23.5 ± 0.8 kg/m2Study 2:
Group 1: T2DM (n = 14; 4
Males; 10 Females)
Age: 40–60 years
(Mean 48 ± 2.1 years);
BMI: <30 kg/m2
(Mean 28.9 ± 1 kg/m2)
Group 2: ‘Healthy’
(n = 7; 4 Males; 3 Females)
Age: 25–54 years
(Mean 21.1 ± 1.2 years)
BMI: <25 kg/m2
(Mean: 22.2 ± 0.6 kg/m2)
Determine glycemic index
of Nopal and Effect of
nopal consumption on
blood GLU
Fasted (12 h)
Treatment: 150 g steamed Nopal
Study 1:
Length: Single consumption
Dried nopal (CLD): 24.8% CHO; 32.2% insoluble fiber; 4.8% soluble fiber;
<1.9% fat; 15.4% PRO.
50 g of Nopal vs. 50 g GLU
Control trial
Study 2:
Length: Single consumption
High CHO breakfast: 300 kcal; 89% CHO; 6% PRO; 5% fat (240 mL apple
juice, 55.6 g white bread, 21 g strawberry jam)
High Soy Protein Breakfast: 344 kcal; 42.2% CHO, 40.7% PRO; 16.9% fat
(61.5 g soy hamburger, 230 mL soymilk beverage).
Washout period: 1 week
Cross-over trial
GLU
INS
Study 1:
Blood (capillary and
Venous)
15, 30, 45, 60, 90 and 120
min
Study 2:
Blood (capillary and
Venous)
15, 30, 45, 60, 90, 120 and
150 min
Study 1:
Nopal ingestion (vs. GLU) ↓ AUC GLU
(p < 0.001)
Glycemic index on Nopal: 32.5 ± 4.0
Nopal ingestion (vs. GLU) ↓ AUC INS
(p < 0.05)
Insulinemic index of Nopal: 36.1 ± 6.1
Study 2:
High CHO Breakfast + Nopal= ↓ GLU at
30 min (p < 0.05), 45 min (p < 0.01),
60 min (p < 0.01);
↓ AUC GLU (p < 0.001).
↓ AUC of INS (p < 0.05) in diabetes
patients
High soy protein breakfast: ↓GLU
(p < 0.001) regardless of group; Nopal
GLU was NS (p > 0.05)
Nopal INS was NS (p > 0.05)
Castaneda-
Andrade et al.
(1997) [53]
T2DM (n =8;
2 Males; 6 Females)
Age: 58.4 years
(Range: 48.9–67.8 years)
The effect of Opuntia
streptacantha on
hyperglycemia (CLD) in
T2DM
Length:
Single consumption
Treatment:
Group A: 250 mg CLD capsule
Group B: placebo capsules
Randomized cross-over trial
12 h fasted blood (0, 60,
120, 180 min)
GLU
INS
↓ GLU (60 + min) both groups;
↓ GLU (basal vs. 180 min) (p < 0.001) for
both groups
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Table 2. Cont.
Author (Year) Participant, Sample Size Aim Intervention Relevant Outcomes Results (Treatment vs. Placebo)
Long-term results
Frati et al.
(1983) [46]
11 Males; 18 Females (n =29)
‘Healthy’: (n = 8)
‘0–8% overweight; Mean 8%’
Obese: (n = 14)
‘18–70% overweight’;
Mean 35%
T2DM: (n = 7); 1–5%
overweight; received
tolbutamide during trial
The effect of ‘Nopal’ (CLD;
(Opuntia streptacantha)
consumption on serum
lipids, glycemia and body
weight
Length: 10 days
Treatment:
(1) Regular diet
(2) Regular diet + 100 g broiled CLD before meals, 3 × day; 10 days
Total per day: 300 g CLD
Total: 3000 g/10 days
Control trial
GLU (m mol/DI)
(Fasting; Pre- VS.
Post-treatment)
GLU: ↓ (vs. fasting blood GLU) T2DM
(p < 0.001), ‘non-T2DM’ (p < 0.05)
Guevare-Cruz
et al. (2012)
[49]
‘Healthy’ (n = 67)
Age: 20–60 years
BMI: 25–39.9 kg/m2
The effect of dietary
pattern on biochemical
markers
2 weeks prior: Reduced energy diet, low-saturated fay and
low-cholesterol diet. (15 × eating plans: 50–60% CHO; 15% PRO; 25–35%
FAT; <7% saturated fat, <200mg/d cholesterol, 20–30 g/d fiber.)
Treatment:
Length: 2 months
Group 1: Controlled Dietary Pattern
Group 2: Placebo
Dietary Pattern: 100 g nopal (CLD), 4 g chia seeds, 22 g oats, 32g soy bean
proteins, 0.02 g sweetener (‘Splenda’), 1 g flavoring
Placebo: 30 g calcium caseinate, 30 g maltodextrin, 0.02 g sweetener
(‘Splenda’), 1 g flavoring.
Single-center, randomized, placebo-controlled, double-blind, parallel-art
study
Pre/Post intervention
OGTT: 75 g GLU (120 min)
GLU
INS
No change in either treatment group for
GLU
INS
AUG:
No difference in OGTT.
↑ INS in OGTT of Dietary Pattern
(p < 0.05)
↑ Significant diet and time interaction
between pre/post diet intervention on
INS (p < 0.01)
Linares et al.
(2007) [52]
Females (n = 59)
Age: <35 years (10.29%)
35–45 years (27.94%)
45–55 years (41.18%)
>55 years (20.59%)
BMI: 25–40 kg/m2
Placebo group: n = 33
Treatment group: n = 35
Length: 6 weeks- with ‘balanced diet’ (2000 kcal; 38% Fats; 17% PRO;
45% CHO) and 30 min of physical activity/day.
Treatment: 3 × 1.6 g ‘NeOpuntia©’ capsules, after meal/day with water.
Control: 3 × Placebo Capsule
Monocentric, randomized, double-blind, placebo-controlled study
Prevalence of Fasting
GLU (>0.95 g/L)
GLU:
Treatment group remained the same
during study period (n = 15).
↑ in placebo group (n = 20→22).
Bacardi-Gascon
et al. (2007)
[55]
T2DM
(n = 36)
Age: 47–72 years
GLU: 8.0 ± 2 mmol/L
BMI: 24.86 ± 3.76 kg/m2
Group 1: n = 11
Group 2: n = 9
Group 3: n = 9
Post-prandial glycemic
response to nopal (CLD)
Length: 3 weeks
Treatment: 1 ×week/3 weeks (fasted)
(1) Chilaquiles (corn tortilla, vegetable oil, tomato sauce, cheese, pinto
beans) (with vs with-out CLD)
(2) Burrito (scrambled egg, tomato, onion, vegetable oil, flour tortilla,
pinto beans) (with and without-CLD)
(3) Quesadillas (flour tortilla, low fat cheese, avocado, pinto beans)
(with and without CLD)
7-day washout periods
Control: Chilaquiles, Burrito and Quesadillas without cladode
Placebo-controlled Cross-over trial
Fasted Baseline: 0, 50g of
white bread at 15, 30, 45,
60, 90 and 120 min
GLU
↓ GLU over all; (p = 0.029)
Group 1:
↓ AUC (with vs. without; p = 0.013)
↓ Glycemic index white bread and GLU
(p = 0.018)
Group 2:
↓ AUC (with vs. without CLD; p = 0.011)
↓ Glycemic index of white bread and
GLU (p = 0.025)
Group 3:
↓ AUC (with vs. without CLD; p = 0.019)
↓ Glycemic index of white bread and
GLU (p = 0.027; p =0.025)
NNIDM: Non-Insulin Dependent Diabetes Mellitus; BMI: Body Mass Index; CLD: Cladode; GLU: Blood Glucose; INS: Serum insulin; NS: Not Significant; h-hours; OGTT: Oral Glucose
Tolerance Test; AUC: Area Under the Curve ↓: Decrease; ↑: Increase.
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Table 3. The summary of the effect of combined or unidentified Opuntia spp. fruit and cladode consumption on blood glucose and insulin in human trials [36,51,56,57].
Author (Year) Participant, Sample Size Aim Intervention RelevantOutcomes Results (Treatment vs Placebo)
Acute Results
Deldicque et al.
(2013) [56]
‘Healthy’
Males (n = 11)
Age: 21.1 ± 0.9 years
Weight: 74.4 ± 4.2 kg
Effect of:
(1) ‘OpunDia’
(2) ‘OpunDia’ + Leu
(Leu)
Supplementation on INS
stimulation
Length: Single Consumption
Fasted; post-30 min endurance exercise (70% VO2); 75 g
of GLU with treatment at: 0 min and 60 min.
Treatment:
(1) Placebo ‘LUVOS Heilerde’
(2) 1000 mg ‘OpunDia©’
(3) 3 g Leu
(4) 1000 mg ‘OpunDia©’ + 3 g Leu
1-week wash-out
Randomized double-blind cross-over study
OGTT
(2 h)
INS
GLU
OGTT:
INS higher with ‘OpunDia+Leu’, after 60 min (vs.
Placebo)
INS:
OpunDia+Leu ↑40% at 2 h (vs. placebo) (p < 0.05)
OpunDia ↑ 2 h (vs. Placebo) (p < 0.05)
AUC: OpunDia ↑ (p = 0.06)
AUC: OpunDia+Leu (p < 0.05)
Leu-no effect
GLU:
OpunDia ↓GLU by 7% (90 min), 15% (120 min) (vs.
placebo; p < 0.05)
AUC: ↓ OpunDia vs. placebo (p < 0.05)
Van Proeyen et al.
(2012) [57]
‘Healthy’
Males (n = 6)
Age: 21.0 ± 1.6 years;
Weight: 78.1 ± 6.0 kg;
The effect of ‘OpunDia’
supplementation on blood
GLU and INS before and
after exercise
Length: Single consumption
Standardized Dinner: 860 kcal; 73% CHO, 14% fat, 13%
PRO); 12 h Fast
Exercise: 30 min submaximal endurance
Treatment: 500 mg, 1000 mg, 1500 mg
‘OpunDia’Placebo ‘LUVOS Heilerde’
Pre- and post- exercise:
OGTT (2 h)-75 g GLU
* Post-exercise OGTT, additional bolus at 60 min
2-week washout period
Double-bind Placebo-controlled crossover study
30, 60, 90, 120
min capillary
and Venous
blood collection
GLU
INS
Pre-exercise:
↓GLU: 30 min (p < 0.10), 60 min (p < 0.02).
60 + min = NS (p > 0.05).
↓GLU AUC (p < 0.03)
↑ INS (p < 0.01).
↑ INS: 30 min (p < 0.03)
INS AUC = NS (p > 0.05)
Post-exercise:
↓ GLU: 60 min (p < 0.04)
↓ GLU AUC (p < 0.03)
INS = NS (p > 0.05)
Godard et al. (2010)
[36]
Obese (n = 29; Males and
Females)
BMI: 30–35 kg/m2
Age: 20–50 years
Acute: n = 29
Chronic:
Treatment: n = 15
Control: n = 14
Determine the acute and
chronic effects of
‘OpunDia’
Length: Single consumption
Treatment: 200 mg ‘OpunDia’
Placebo: 200 mg microcrystalline cellulose
Acute trial:
400 mg ‘OpunDia’ 30 min prior to 75 g GLU (OGTT);
Chronic trial:
Length: 16 weeks
2 × Treatment (200 mg) or Placebo
Randomized, Double-blind, placebo-controlled trial
Acute:
GLU
Blood time: 0, 30,
60, 90, 120 min
Chronic:
OGTT
GLU
INS
Acute:
‘OpunDia’ vs Fasted: 60, 90 and 120 min (p < 0.05)
Chronic:
GLU:
Pre/Post- ‘OpunDia’: ↓ 60, 90 and 120 min (p < 0.05)
Pre/Post Placebo: ↓ 60, 90 min (p < 0.05)
INS:
Pre/Post ‘OpunDia’: NS (p > 0.05)
Pre/Post Placebo: NS (p > 0.05)
Long-term results
Guevara-Arauza
et al. (2011) [51]
‘Healthy’ (n = 28;
12 Males, 16 Females)
To determine
bio-functional effects of
nopal (CLD) and PP fruit
products
Length: 3 weeks
Treatment: Supplement diet with 40 g Bars: Control-bar
vs ‘Nopal (32%) with PP pulp Jam’ bar (15 g); and 100 g
Tortillas vs. Tortillas with Nopal (48%).
Dose: Twice a day, three-weeks. Control trial
Fasted (8 h)
blood samples;
Tortilla VS. control:
↓ GLU (p < 0.05)
Tortilla and PP pulp jam bars: ↓ GLU (p < 0.05)
PP: Prickly Pear; OGTT: Oral Glucose Tolerance test; CHO: Carbohydrate; PRO: Protein; GLU: Blood Glucose; INS: Serum insulin; Leu: Leucine; AUC: Area Under the Curve; NS: Not
Significant; ↓: Decrease; ↑: Increase; Note: ‘OpunDia©’ is a capsule supplement containing 75% Cladode and 25% PP fruit extract (Solvent: Water).
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Table 4. Risk of bias summary for included studies in this systematic review.
Selection Bias Performance Bias Detection Bias Attrition Bias Reporting Bias
Other BiasRandom Sequence
Generation
Allocation
Concealment
Blinding of Participants
and Personnel
Blinding of Outcome
Assessment
Incomplete
Outcome Data
Selective
Reporting
Prickly Pear Fruit
Khouloud et al. (2016) [39] High Unclear High Unclear Low Low Unclear
Wolfram et al. (2002) [40] High Unclear High Unclear Low Low Unclear
Pimienta et al. (2008) [42] High Unclear High Unclear Low Low Unclear
Wiese et al. (2004) [41] Low Low Low Unclear Low Low Unclear
Cladode/leaf
Frati et al. (1983) [45] Unclear Unclear High Unclear Low Low Unclear
Frati et al. (1983) [46] Unclear Unclear High Unclear Low Low Unclear
Frati et al. (1987) [48] Unclear Unclear High Unclear Low Low Unclear
Frati et al. (1991) [43] High Unclear High High Low Low Unclear
Frati et al. (1991) [44] Unclear Unclear High Unclear Low Low Unclear
Frati et al. (1988) [47] High Unclear High High Low Low Unclear
Frati et al. (1990) [54] High Unclear High Unclear Low Low Unclear
Guevare-Cruz et al. (2012) [49] Low Low Low High Low Low Unclear
Lopez-Romero et al. (2014) [50] Unclear Low High Unclear Low Low Unclear
Castaneda-Andrade et al. (1997) [53] Unclear Unclear Low Unclear Low Low Unclear
Linares et al. (2007) [52] Unclear Low Low Unclear Low Low Unclear
Bacardi-Gascon et al. (2007) [55] Low Unclear High Unclear Low Low Unclear
Combination of Fruit and Cladode/Leaf
Deldicque et al. (2013) [56] Low Unclear Low Unclear Low Low Unclear
Van Proeyen et al. (2012) [57] Low Unclear Low Unclear Low Low Unclear
Godard et al. (2010) [36] Low Unclear Low Unclear Low Low Unclear
Guevara-Arauza et al. (2011) [51] Unclear Unclear High Unclear Low Low Unclear
The forms of bias considered included; selection, performance, detection, attribution, reporting and ‘other’ biases, which were scored either ‘low’, ‘high’ or ‘unclear’.
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3.2. Results of Included Studies
3.2.1. Results of Opuntia spp. Fruit Included Studies
The studies included in the category of the PP fruit (Table 1), utilized various forms such fruit
pulp [40], the juice from the fruit pulp [39], fruit peel [42] and fruit extracts [41]. Nearly all of these
studies were conducted in males, except for one study conducted in females (n = 10 female; T2DM) [42]
and one in males and females (n = 55; 18 female; 37 male) [41]. Typically, studies in this category were
matched with placebo treatments (capsule) [41] or control treatments (GLU control solution, dietary
patterns) [39,40,42] and duration of treatment ranged from single consumption [41,42], short term
(2–5 weeks) [39,42] and long term (16 weeks) [40].
Supplementation with the purple PP fruit pulp juice over the period of two weeks [39] resulted in
significant differences in fasting GLU levels in ‘healthy’ males undergoing an exercise intervention
(p = 0.01). Wolfram et al. (2002) [40] using a PP fruit pulp (250 g/day; 8 weeks) also reported significant
decreases in fasting GLU (p < 0.005) of participants with hypercholesterolemia and hyperlipidemia;
and INS (p < 0.005) in participants with hypercholesterolemia but not hyperlipidemia (p > 0.05).
Pimienta et al. (2008) [42] reported no significant effects of PP fruit after a single consumption of PP
fruit peel, in ‘healthy’ subjects (n = 14; p > 0.05). Similarly, there were no significant lowering effects
inT2DM participants (n = 10) after 5 weeks of treatment for both blood GLU and INS (Both p > 0.05),
using Oral GLU Tolerance Tests (OGTT) and ‘pre-’ and ‘post-’ intervention serum samples. In addition,
Wiese et al. [41] examined the effect of commercially available PP fruit extract capsules on reducing
symptom severity in ‘healthy’ participants with induced alcohol toxicity and reported no significant
differences between treatment and placebo on serum GLU (p > 0.05).
3.2.2. Results of Opuntia spp. Cladode Included Studies
Studies on the cladode of Opuntia spp. included numerous preparations of these products
as a food delivery method such as; cooked (broiled, grilled) [43,44,47,54], powders [45,49,50],
capsules [52,53] and new products such as tortillas including the cladode [55]. The cladode was
studied in; ‘healthy’ [43–46,48–52], obese [46,52], T2DM [43–48,50,54,55] participants as control [45–52]
and cross-over trials [50,53–55]. In most of the studies, intervention was matched with a placebo [52]
or control interventions [43,45–50,53–55]. The interventions were predominantly based on single
consumption [43–45,47,48,50,54], although two studies included short term (2–3 weeks) [53,55] and
two studies included long terms (6–10 weeks) [46,52] treatments.
Interestingly, majority of the studies reported in this systematic literature review using the cladode
as a food delivery product were from Frati and colleagues, where seven articles were included as
a part of a separate trial. Firstly, a study by Frati et al. (1983a) demonstrated significant effects in
reduction of GLU (p < 0.01–0.05) and INS (p < 0.01–0.02) post-prandial (0–3 h) with ingestion of 100g
of broiled cladode in healthy males [45]. When consumed for a longer period (10 days), a study by
Frati et al. (1983b) [46] indicated that consumption of the previously established quantity of cladode
(100g) had significant reductions in fasted serum GLU (mean: 3.5 mmol/L) for T2DM participants
(n = 7; p < 0.01). Additionally, significant reductions were also reported in ‘non-diabetic’ participants
(mean: 0.021 mmol/L p < 0.05). In some cases, the participants of certain comparisons were not defined
to the reported study groups but rather generalized as ‘healthy’ (n = 8) and ‘obese’ (n = 14; combined
study groups) [46]. A study that followed [48] built on the single consumption investigations, where
Frati et al. (1987) considered the effects of treatment and OGTT protocol interactions (cladode; cladode
before dextrose bolus; cladode mixed with dextrose) to find significantly lower serum GLU (p < 0.025;
vs. water) at 60 and 180 min in healthy adults. No significant (p > 0.05) effects were reported for
serum INS between the treatments [48]. Comparisons between single consumption of Opuntia spp.
cladode and zucchini squash (500g) in T2DM participants (n = 48) were drawn on both GLU and
INS parameters [47]. Consumption of the broiled cladode resulted in significant reductions in serum
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GLU (1 h 8.5 ± 2.4%; 2 h 10.7 ± 1.4%; 3 h 17.6 ± 2.2% µU/mL; p < 0.01–0.025) and INS (p < 0.001; 1 h
22.5 ± 5.2%; 2 h 38.7 ± 6.3%; 3 50.2 ± 8.0%) [47].
A study by Frati et al. (1990) [53] continued to examine the effects of various cladode processing
techniques [48] (broiled, raw blended, broiled and blended, blended and broiled; 500 g) on fasted
serums GLU in healthy participants. This study it was reported significant reductions in 120 and
190 min (p < 0.001), although no significant (p > 0.05) effects were observed between processing
techniques [58]. Investigations into the effects of cladode consumption with established volume and
preparation on GLU and INS continued into T2DM participants, whereby the timing of sequential
consumption was considered [44]. In this study, there was a significant reduction (p < 0.01) is fasting
serum GLU in T2DM participants (2 h, 36.8 mg/dl; 4 h, 92 mg/dl; 6 h, 49 mg/dl) but not in healthy
participants (p > 0.05) [44]. A study examining the effect of grilled cladode (500 g) in matched T2DM
(n = 14) and healthy (n = 14) participants reported significant reductions in GLU (1 h: 1.19 ± 0.21 mM,
p < 0.005; 2 h: 1.57 ± 0.28 mM, p < 0.005; 3 h: 2.26 ± 0.25 mM, p < 0.001) and INS (p <0.01; 1 h: 12.3 ± 15.9;
2 h: 3 h: 36.9 ± 10.8 pM; 56.4 ± 10.8 pM) in T2DM but not in a healthy group [43]. These studies
indicate that the consumption of cladode prepared in various ways (cooking procedures) significantly
reduced blood GLU and INS levels in T2DM participants. Despite the significant reductions of GLU
and INS with consumption of Opuntia spp. Cladode in T2DM participants, there is limited evidence to
support the beneficial effects of the vegetable consumption in ‘healthy’ participants.
The remaining included articles considering cladode products in different forms such as
an extract in a capsule [52,53] a meal replacement [49] and in combination with food [49,50,55].
Castaneda-Andrad et al. (1997) [53] reported that single dose cladode consumption, using a capsule
(250 mg) significantly decreased serum GLU (319–220 mg/dL) in individuals living with T2DM
compared with placebo (p < 0.01). In addition, 6 weeks of supplementation of cladode extracts,
provided as a capsule (‘NeOpuntia’; 3 × 1.6 g), had no effect on glucose associated risk factors of
Metabolic Syndrome in a female cohort [52].
Cladode was also studied in combination with other foods, and it was provided in addition
to foods incorporated or provided in a blinded form. A study by Lopez-Romero et al. (2014) [50]
conducted two trials within the same paper. In the first experiment, these authors investigated the
glycemic responses to consumption of cladode powder (50 g) in healthy participants. The powder
significantly lowered serum GLU (p < 0.001) and produced a glycemic index score of 32.5 ± 4.0,
and insulinemic index of 36.1 ± 6.1, upon ingestion. In the second experiment, the effect of cladode
consumption in combination with various breakfasts (high carbohydrate; high soy protein) on serum
GLU and INS in T2DM (n = 14) and healthy participants (n = 7) was investigated [50]. The results
showed that T2DM participants nopal consumption in combination with a high carbohydrate breakfast
incurred significant decreases in serum GLU (30 min, 45 min and 1 h; p < 0.01), GLU by Area Under
the Curve (AUC reduction 287 ± 30 mmol/L; p < 0.001), with no significant differences reported in
serum INS [50]. Significant differences were also observed between high carbohydrate and high soy
protein breakfasts in GLU levels (p < 0.001).
Lopez-Romero et al. (2014) reported no significant differences (p > 0.05) in cladode powder
ingested with a high-soy protein breakfast for parameters of GLU or INS in participants with T2DM,
but there was a significant difference for INS AUC in healthy participants (decrease; p < 0.01). A study
by Bacardi-Gascon et al. (2007) [55] investigated the cladode consumption by incorporating it into
three meals; chilaquiles, burritos, and quesadillas with or without the cladode. Significant decreases in
serum GLU (AUC) were apparent in all three meals (chilaquiles p = 0.018; burritos p = 0.025; quesadillas
p = 0.019). A separate study by Guevare-Cruz et al. (2012) investigated the effects of a dietary pattern
containing cladode among other ingredients to include chia seeds, oats, and soy protein against a
less nutrient and bioactive dense placebo dietary pattern over a 2-month period [49]. The mentioned
dietary pattern was found to have a significant difference on AUC for INS (p < 0.05) and diet-time
interactions for INS as well (p < 0.001). The GLU lowering effects of Opuntia spp. of the cladode are
supported by literature; however, more evidence is recruited to make conclusions regarding INS.
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3.2.3. Results of Combined or Unspecified Opuntia spp. Included Studies
Combined Opuntia spp. plant products (Table 3) were studied in both males and females, using the
specifically-formulated tortillas and bars [51] or commercially available ‘OpundDia©’ capsule dietary
supplement, reported to contain 75% Cladode and 25% PP fruit extract. The Opuntia spp. products
were investigated with control [36,51] and cross-over [56,57] designed trials in healthy [51,56,57] and
obese [36] participants. Investigations into combined fruit and cladode products were consistent,
where controls were established as placebo capsules [36,56,57] or formulated products for investigation
into single consumption models.
Investigations considering combined Opuntia spp. products considered the efficacy of the
established products, with the exception of Guevera-Arauza et al. (2011) [51], who developed
several products. Acute and chronic effects of ‘OpunDia©’ in obese participants were investigated
by Godard et al. (2010) [36]. Acute trial (n = 29; 400 mg) indicated significant differences in serum
GLU for time points 1, 2, and 3 h (p < 0.05) between treatment and control (placebo capsules).
Guevera-Arauza et al. (2011) [51] concluded that the chronic supplementation of ‘OpunDia©’ over
16 weeks induced significant reductions in GLU both pre-and post-treatment (p < 0.05) and placebo
(p < 0.05); and had no significant effects on INS [36].
A study by Van Proeyen et al. (2012) [57] investigated dose of ‘OpunDia©’ treatments (500 mg,
1000 mg, and 1500 mg) in combination with exercise interventions. Significant reductions in serum GLU
were reported in pre-exercise (30 and 60 min; p < 0.10–0.02) and post-exercise (60 min; p < 0.04); and
significantly increases INS during pre-exercise at 30 min (p < 0.03), but not post-exercise [57]. A study
by Deldicque et al. (2013) [56] continued in active participants, investigating the interaction between
‘OpunDia©’ in combination with amino acid, leucine, on INS stimulation in ‘healthy’ males following
(endurance) exercise [56]. In this study, there was a significant increase in INS with ‘OpunDia©’
(p < 0.05) and in combination with Leucine (p < 0.05); and significant decreases in GLU with ‘OpunDia©’
(p < 0.05) but no other synergistic combinations.
A study by Guevera-Arauza et al. (2011) [51] differed from other included combined Opuntia spp.
in that the Opuntia spp. products were developed by investigators for the purpose of the study. The aim
of this study was to determine the effect of the Opuntia spp. PP fruit and cladode in placebo and
fortified food products including various bars and tortillas were tested on serum GLU. The results
demonstrated a significant lowering effect (p < 0.05; 4.43 mmol/L) on serum GLU in healthy participants
upon product consumption.
4. Discussion
The Opuntia spp. cacti and its components have been reported to have ‘anti-diabetic’ or
‘anti-hyperglycemic’ properties [56]. However, confusion exists within the literature between which
Opuntia spp. components are responsible for the reported health effects [34,56]. The Opuntia spp.
cladode demonstrated significant positive health effects, indicating its potential as a functional food
for potential short-term treatment of hyperglycemia in multiple sample participants.
Proposed mechanisms underlying how plant-based products may induce anti-hyperglycemic
effects include individual or combined effects via the modulation of gastrointestinal absorption
or regulation of INS secretion and sensitivity [56]. The anti-hyperglycemic activities provided by
plant-based products are diverse and are a result of a multiple contributing factors, including the
presence of INS-like substances or ‘factors’ within the plant material [59], upregulation of INS via
β-cells [60], increased insulin binding activity of receptors [60], increase GLU metabolism [61], high
fiber content reducing the rate of absorption [62], or potential regeneration of pancreatic cells [63].
Various aspects of potential mechanisms are proposed following positive effects of specific Opuntia spp.
products reported within this review. The findings of this review provide rationale for the use of
Opuntia spp. products in applications such as incorporation into functional foods or nutraceuticals,
given the additional substantial bioactive contents [18–31].
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4.1. Opuntia Ficus Indica Fruit
Overall, the results of this systematic review suggest no significant effects on blood GLU [39,41,42]
and INS [42], upon investigations into Opuntia ssp. PP fruit pulp [40], pulp juice [39], fruit peel [42],
and fruit extracts [41]. The conclusions made regarding the results of this systematic review do
consider the disagreements of significant differences in the reduction of GLU in hypercholesterolemic
(n = 12) and hyperlipidemic (n = 12) sample participants; and INS in a hypercholesterolemic sample
population (n = 12) [40]. Although serum GLU was investigated in every included study regarding the
PP fruit, it is important to recognize that INS was only studied in two of the four included fruit-based
investigations [40,42]. The conclusions drawn with respect to Opuntia spp. fruit are limited by high
risk of bias with relation to selection, performance, and detection biases, but did show strengths in
attribution and reporting bias.
Interestingly, the widely accepted associations of fiber as an anti-hyperglycemic effect [62] were
observed within the fruit-based studies included in this review. Anti-hyperglycemic effects are often
reported in trial foods with a higher fiber content [62], such as that expected of fruit flesh, unlike
a majority of the investigations within this review. The included fruit-based studies investigating
fruit products with substantially less fiber to include; juice [39], peel [42] and extracts [41]. Future
research should investigate the effects of PP fruit consumption regarding the INS-GLU relationship,
with consideration of fiber. The results of this review do not encourage the prescription of PP fruit as
an alternative medicine in treatment of hyperglycemia or associated conditions, until further evidence
is developed.
4.2. Opuntia Ficus Indica Cladode Leaf
Opuntia spp. cladode consumption was associated with significantly lower serum GLU in healthy,
obese [46,52], and individuals with T2DM [43,44,46,47,50,53–55]. Of the 12 included cladode-based
investigations, 6 studies investigated INS responses [43,45,47–50]. Conclusions regarding INS were not
definitive, due to conflicting evidence [43]. The majority of the sourced results indicated significant
changes in serum INS on cladode consumption in healthy participants [45] and individuals with
T2DM [43,47,50]. Conflicting evidence with respect to INS was seen in active and placebo diets
including the cladode, as a whole product [50] or as a powder (n = 67) [49]; and studies investigating
interactions between OGTT timing and cladode consumption, also indicated no significant effects [48].
Consistent with previous hypotheses regarding GLU lowering mechanisms, the cladode leaf is
reported to contain substantial amounts of fiber [34,62]. Currently, due to the cladode’s fiber content,
it is utilized for the development of many food products and supplements, such as flours and fiber
supplements [34]. Future research should consider investigation into other potential mechanisms of
action, and inter-relationships should be considered regarding the anti-hyperglycemic effects observed
via consumption. In conclusion, the consumption of the cladode has noticeable effects of hyperglycemia;
however, it should be recommended with caution and consideration of commonly-associated effects of
food with high fiber content.
4.3. Opuntia Ficus Indica as Combined Fruit and Cladode Leaf
Of the included articles within this review, four were identified as combined Opuntia spp. products;
‘OpunDia©’ capsule-based investigations [36,56,57] and cladode-based food products [49]. Both
Opuntia spp. product investigations reported significant reduction in serum GLU. To our knowledge,
the literature surrounding the effects of Opuntia spp. products on INS, were only studied using the
‘OpunDia©’ capsule; however, they reported conflicting results [36,56,57].
The beneficial effects of the combined supplements (cladode and fruit) may be due to the greater
cladode to fruit proportions within the ‘OpunDia©’ capsules. Noticeably, the studies examining the
effects of the combined Opuntia spp. products do not control for the anti-hyperglycemic effects of
fiber [62]. A study by Deldicque et al. (2013) [56] based investigation into ‘OpunDia©’ on the proposed
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mechanism of direct upregulation of INS by the Opuntia ficus indica spp, rather than indirect production
of INS, in response to increased serum GLU. Multiple studies propose the direct insulinogenic actions
of the Opuntia spp. products, described as acute and rapidly acting [56], a result of upregulation of
pancreatic β-cell INS secretion [56,57]. Although, a study by Van Proeyen et al. (2012) [57] proposed a
dualist mechanism stemming from both GLU-induced and GLU-independent INS production of the
combined Opuntia spp. product consumption. However, this finding was in a population undergoing
an exercise intervention, in which they were characteristically more susceptible, or had improved INS
sensitivity [57]. The use and effectiveness of combined Opuntia spp. products are largely specific to
the product, where further evidence is required on mechanisms of action before making conclusions
regarding the effectiveness or advised supplementation.
5. Conclusions
The findings of this systematic literature review indicate that the cladode leaf and selection of
combined Opuntia spp. products (typically containing a mix of cladode leaf and fruit) may have
significant effects of serum GLU reduction. However, effects on INS were less consistent. The PP fruit
was found to not have significant ‘anti-hyperglycemic’ effects, though the definitive evidence was
conflicting. This suggests that there might be variability in the potential anti-hyperglycemic effects of
different plant parts of Opuntia spp., which warrants further investigation. Study characteristics
including design, exposure, quantity, and participants, as well as the treatment product and
compositions, varied extensively, limiting the conclusions within this review. Future research should
investigate the serum glucose-insulin relationships within consumption-based investigation and the
inter-relationships within the proposed mechanisms of action, ideally following standardized and
reproducible methodologies.
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